{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:08:28Z","timestamp":1769170108217,"version":"3.49.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T00:00:00Z","timestamp":1555718400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s40618-019-01051-4","type":"journal-article","created":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T15:02:22Z","timestamp":1555772542000},"page":"1361-1363","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of CFTR-modulating drugs on GH-IGF-1 axis impairment in adult patients with cystic fibrosis"],"prefix":"10.1007","volume":"42","author":[{"given":"C.","family":"Pascucci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. V.","family":"De Biase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Savi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Quattrucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Gnessi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lubrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lenzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,20]]},"reference":[{"issue":"Suppl 1","key":"1051_CR1","first-page":"7","volume":"58","author":"A Ballinger","year":"2002","unstructured":"Ballinger A (2002) Fundamental mechanisms of growth failure in inflammatory bowel disease. Horm Res 58(Suppl 1):7\u201310","journal-title":"Horm Res"},{"issue":"1","key":"1051_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1210\/er.2015-1026","volume":"37","author":"SC Wong","year":"2016","unstructured":"Wong SC, Dobie R, Altowati MA, Werther GA, Farquharson C, Ahmed SF (2016) Growth and the growth hormone insulin like growth factor 1 axis in children with chronic inflammation: current evidence, gaps in knowledge, and future directions. Endocr Rev 37(1):62\u2013110","journal-title":"Endocr Rev"},{"issue":"8","key":"1051_CR3","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/BF03346643","volume":"33","author":"M Poggi","year":"2010","unstructured":"Poggi M, Pascucci C, Monti S, Pugliese P, Lauri C, Amodeo G, Girelli G, Toscano V (2010) Prevalence of growth hormone deficiency in adult polytransfused \u03b2-thalassemia patients and correlation with transfusional and chelation parameters. J Endocrinol Investig 33(8):534\u2013538","journal-title":"J Endocrinol Investig"},{"issue":"5","key":"1051_CR4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s40618-017-0784-x","volume":"41","author":"C Pascucci","year":"2017","unstructured":"Pascucci C et al (2017) Deregulation of the growth hormone\/insulin-like growth factor-1 axis in adults with cystic fibrosis. J Endocrinol Investig 41(5):591\u2013596","journal-title":"J Endocrinol Investig"},{"issue":"10","key":"1051_CR5","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1080\/17512433.2017.1378094","volume":"10","author":"MN Bulloch","year":"2017","unstructured":"Bulloch MN et al (2017) Lumacaftor\/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation. Expert Rev Clin Pharmacol 10(10):1055\u20131072","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2014","key":"1051_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","volume":"13","author":"F Goor Van","year":"2014","unstructured":"Van Goor F, Yu H, Burton B, Hoffman BJ (2014) Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros 13(2014):29\u201336","journal-title":"J Cyst Fibros"},{"key":"1051_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","volume":"373","author":"E Claire","year":"2015","unstructured":"Claire E, Wainwright MB et al (2015) Lumacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373:220\u2013231","journal-title":"N Engl J Med"},{"issue":"1","key":"1051_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1001\/archpedi.1958.02060060008002","volume":"96","author":"H Shwachman","year":"1958","unstructured":"Shwachman H, Kulczycki LL (1958) Long term study of one hundred five patients with cystic fibrosis; studies made over a five to fourteen years period. AMA J Dis Child 96(1):6\u201315","journal-title":"AMA J Dis Child"},{"issue":"4","key":"1051_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.pcl.2016.04.009","volume":"63","author":"SM Blackman","year":"2016","unstructured":"Blackman SM, Tangpricha V (2016) Endocrine disorders in cystic fibrosis. Pediatr Clin N Am 63(4):699\u2013708","journal-title":"Pediatr Clin N Am"},{"issue":"S45","key":"1051_CR10","first-page":"438","volume":"51","author":"A Kelly","year":"2016","unstructured":"Kelly A, Sheikh S, DeLeon D, Camburn D, Peleckis A, Rickels M, Rubenstein RC (2016) B-cell secretory capacity improves in cystic fibrosis with ivacaftor therapy. Pediatr Pulmonol 51(S45):438","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"1051_CR11","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/j.jcf.2015.10.012","volume":"15","author":"R Tsabari","year":"2016","unstructured":"Tsabari R, Elyashar HI, Cymberknowh MC, Breuer O, Armoni S, Livnat G, Kerem E, Zangen DH (2016) CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation. J Cyst Fibros 15(3):e25\u2013e27","journal-title":"J Cyst Fibros"},{"issue":"11","key":"1051_CR12","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1210\/js.2017-00362","volume":"1","author":"JC Yoon","year":"2017","unstructured":"Yoon JC (2017) Evolving mechanistic views and emerging therapeutic strategies for cystic fibrosis-related diabetes. J Endocr Soc 1(11):1386\u20131400","journal-title":"J Endocr Soc"},{"issue":"5","key":"1051_CR13","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/thoraxjnl-2019-213076","volume":"74","author":"TN Le","year":"2019","unstructured":"Le TN, Schechter MS (2019) Origins of growth deficiencies in cystic fibrosis. Thorax 74(5):423\u2013424","journal-title":"Thorax"},{"issue":"47","key":"1051_CR14","doi-asserted-by":"publisher","first-page":"20571","DOI":"10.1073\/pnas.1015281107","volume":"07","author":"MP Rogan","year":"2010","unstructured":"Rogan MP, Reznikov LR, Pezzulo AA et al (2010) Pigs and humans with cystic fibrosis have reduced insulin-like growth factor 1 (IGF1) levels at birth. Proc Natl Acad Sci USA 07(47):20571\u201320575","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-019-01051-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-019-01051-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-019-01051-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T23:23:47Z","timestamp":1587252227000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-019-01051-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,20]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["1051"],"URL":"https:\/\/doi.org\/10.1007\/s40618-019-01051-4","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,20]]},"assertion":[{"value":"27 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study was approved by the ethics committee of the University and adhered to the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Additionally, the written informed consents were signed by all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}